Replimune Group Inc —— 季度财务数据 (NASDAQ:REPL) | MetaTrader

展开完整图表

Financials

概览声明统计

每季度年度

经营活动产生的现金 -53.73 M-77.02 M-81.21 M-65.95 M -277.91 M 投资活动产生的现金 -7.7 M65.05 M84.17 M75.12 M 216.64 M 融资活动产生的现金 -132 K-158 K324 K10.45 M 10.48 M 自由现金流 -54.87 M-79.76 M-82.56 M-66.09 M -283.27 M

新闻

Replimune stock collapses 64% following FDA rejection

Undercovered Stocks: Zscaler, Aeluma, Devon Energy, And More

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.63%

美国股市上涨；截至收盘道琼斯工业平均指数上涨0.63%

FDA Rejection Sparks Questions On Replimune Drug Approval Path - Replimune Group (NASDAQ:REPL)

Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock Crashes

Replimune: Second CRL May Have Sealed RP1's Fate - It's Hard To See Positives (REPL)

FDA Review Looms As Replimune Faces Weak Technical Setup - Replimune Group (NASDAQ:REPL)

Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback (NASDAQ:IOVA)

RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease

CORT Rises on FDA Nod to Lifyorli in Platinum-Resistant Ovarian Cancer

Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study